Utama › Berat Badan Berlebihan › Nebraska
Kajian klinikal Berat Badan Berlebihan di Nebraska
7 kajian untuk Berat Badan Berlebihan sedang mencari peserta di lokasi di Nebraska.
Bandar di Nebraska
Teks kajian rasmi (Bahasa Inggeris)
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- University Of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07595549A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Omaha Childrens Hospital, Omaha
- Velocity Clinical Research, Omaha
Mengambil pesertaFasa 3
Umur 6 hingga 17 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06672549A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Omaha
- Research Site, Omaha
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Bryan Heart, Lincoln
- University of Nebraska Medical Center, Omaha
- Primary Clinical Research, Papillion
Mengambil pesertaFasa 3
Umur 45 hingga 99 · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07037433A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Omaha
Mengambil pesertaFasa 3Sukarelawan sihat dialu-alukan
Umur 18 hingga 79 · Semua jantina · Dikemas kini 11 Sep 2026 · NCT07654374Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Lincoln
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 3 Sep 2026 · NCT07284901Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Omaha
Mengambil pesertaFasa 3
Umur 18 hingga 79 · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT07654361Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.